Chronic myelogenous leukemia: monitoring response to therapy
1Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology and the University of Adelaide, Adelaide, Australia. susan.branford@health.sa.gov.au
Abstract:
Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia. The current recommendation is that molecular monitoring be performed in place of cytogenetic assessment when a major molecular response (MMR) is achieved. With the more potent kinase inhibitors nilotinib and dasatinib now approved as front-line therapy, more patients will achieve an MMR and will benefit from molecular monitoring. There is a strong correlation between certain BCR-ABL1 levels and the cytogenetic response, which means that molecular monitoring may act as a surrogate for cytogenetic response, but only if the BCR-ABL1 values are converted to the international reporting scale. Furthermore, improvements in the limit of BCR-ABL1 detection and reduction of intra-assay variability are ongoing issues of importance for molecular monitoring. Standardization of molecular methods to accurately assess the patient response also remains a challenge, despite the recent certification of international scale reference materials.
Insights
Molecular monitoring, crucial for chronic myeloid leukemia (CML) patients, is increasingly important with new therapies. Standardized BCR-ABL1 testing on the international scale is vital for accurate response assessment.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Molecular monitoring is essential for managing chronic myeloid leukemia (CML).
- Current guidelines recommend molecular monitoring over cytogenetic assessment upon achieving a major molecular response (MMR).
- Newer kinase inhibitors (nilotinib, dasatinib) are increasingly used as front-line therapy, leading to more patients achieving MMR.
Purpose of the Study:
- To highlight the importance of molecular monitoring in CML management.
- To discuss the role of molecular monitoring as a surrogate for cytogenetic response.
- To identify ongoing challenges and areas for improvement in molecular monitoring.
Main Methods:
- Review of current recommendations and emerging therapies in CML management.
- Analysis of the correlation between BCR-ABL1 levels and cytogenetic response.
- Discussion of technical aspects including detection limits, assay variability, and standardization.
Main Results:
- Molecular monitoring is a key component in CML management, especially with advanced therapies.
- BCR-ABL1 levels, when reported on the international scale, correlate strongly with cytogenetic response, enabling its use as a surrogate.
- Improvements in BCR-ABL1 detection limits and assay standardization are critical for accurate patient response assessment.
Conclusions:
- Molecular monitoring is pivotal for CML patients, particularly with front-line kinase inhibitor use.
- Standardization of BCR-ABL1 quantification using the international scale is crucial for reliable surrogate monitoring.
- Continued efforts in improving detection sensitivity, reducing variability, and standardizing methods are necessary for optimal CML patient care.
More Related Videos
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018